Spatz Madeleine, Wang Yazhou, Lapiere Alexia, Da Costa Gregory, Michaudel Chloé, Danne Camille, Michel Marie-Laure, Langella Philippe, Sokol Harry, Richard Mathias L
INRAE, AgroParisTech, Micalis Institute, Université Paris-Saclay, Jouy-en-Josas, France.
Paris Center for Microbiome Medicine (PaCeMM), Fédération Hospitalo-Universitaire, Paris, France.
Front Med (Lausanne). 2023 Aug 4;10:1087715. doi: 10.3389/fmed.2023.1087715. eCollection 2023.
Antibiotic effects on gut bacteria have been widely studied, but very little is known about the consequences of such treatments on the mycobiota, the fungal part of the microbiota and how the length of administration influences both microbiota. Here, we examined the effect of antibiotics (ATB) on the composition of bacterial and fungal microbiota and how the administration of CNCM I-745 influences both microbiota.
In order to get closer to the human microbiota, the mice used in this study were subjected to fecal microbiota transfer (FMT) using human feces and subsequently called human microbiotaassociated (HMA) mice. These mice were then treated with amoxicillinclavulanate antibiotics and supplemented with during and after ATB treatment to understand the effect of the yeast probiotic on both bacterial and fungal microbiota. Bacterial and fungal microbiota analyses were done using 16S and ITS2 rRNA amplicon-based sequencing.
We showed that the administration of during ATB treatment had very limited effect on the fungal populations on the long term, once the yeast probiotic has been cleared from the gut. Concerning bacterial microbiota, administration allowed a better recovery of bacterial populations after the end of the ATB treatment period. Additionally, 16S and ITS2 rRNA sequence analysis revealed that 7 additional days of administration (17 days in total) enhanced the return of the initial bacterial equilibrium.
In this study, we provide a comprehensive analysis of how probiotic yeast administration can influence the fungal and bacterial microbiota in a model of broad-spectrum antibiotherapy.
抗生素对肠道细菌的影响已得到广泛研究，但对于此类治疗对微生物群中的真菌部分——真菌群的后果，以及给药时长如何影响这两种微生物群，我们却知之甚少。在此，我们研究了抗生素（ATB）对细菌和真菌微生物群组成的影响，以及CNCM I-745的给药如何影响这两种微生物群。
为了更接近人类微生物群，本研究中使用的小鼠接受了用人粪便进行的粪便微生物群移植（FMT），随后被称为人类微生物群相关（HMA）小鼠。然后用阿莫西林克拉维酸抗生素对这些小鼠进行治疗，并在ATB治疗期间及之后补充[具体物质未给出]，以了解酵母益生菌对细菌和真菌微生物群的影响。使用基于16S和ITS2 rRNA扩增子的测序对细菌和真菌微生物群进行分析。
我们发现，一旦酵母益生菌从肠道中清除，在ATB治疗期间补充[具体物质未给出]对真菌种群的长期影响非常有限。关于细菌微生物群，补充[具体物质未给出]使ATB治疗期结束后细菌种群能更好地恢复。此外，16S和ITS2 rRNA序列分析表明，额外7天的[具体物质未给出]给药（总共17天）增强了初始细菌平衡的恢复。
在本研究中，我们全面分析了在广谱抗生素治疗模型中，益生菌酵母给药如何影响真菌和细菌微生物群。
